MELD联合乳酸预测挽救性TIPS治疗难治性静脉曲张出血的死亡
衍生队列6周总生存率58%,MELD评分和动脉乳酸与6周生存独立相关;验证队列6周生存率67%。动脉乳酸≤2.5 mmol/L且MELD≤15者6周生存率>85%,乳酸≥12 mmol/L和/或MELD≥30者死亡率>90%。
要点
- MELD评分和动脉乳酸是挽救性TIPS术后6周死亡的独立预测因素
- 动脉乳酸≤2.5 mmol/L且MELD≤15者6周生存率>85%
- 乳酸≥12 mmol/L和/或MELD≥30者6周死亡率>90%
核心结论
- 挽救性TIPS术后6周死亡率仍高,可通过MELD评分和动脉乳酸预测。
- 动脉乳酸≤2.5 mmol/L且MELD≤15者6周生存率>85%,乳酸≥12 mmol/L和/或MELD≥30者死亡率>90%。
研究设计与样本
- 患者分为衍生队列83例和验证队列81例,比较采用Mann-Whitney和Fisher精确检验。
- 采用Kaplan-Meier曲线及log-rank检验、Cox模型单因素和多因素分析。
主要发现
- 衍生队列6周总生存率为58%,验证队列为67%。
- 多因素分析显示MELD评分(OR 1.064;95% CI 1.005-1.126;P=0.028)和动脉乳酸(OR 1.063;95% CI 1.013-1.114;P=0.032)与6周总生存相关。
- 衍生队列中动脉乳酸≤2.5 mmol/L且MELD≤15者6周生存率100%,乳酸≥12 mmol/L和/或MELD≥30者6周生存率5%。
- 验证队列中相应6周生存率分别为86%和10%。
- 总队列6周再出血率为15.8%,慢加急性肝衰竭分级(OR 1.699;95% CI 1.056-1.663;P=0.040)与再出血独立相关。
关键数值与推荐
- 动脉乳酸≤2.5 mmol/L且MELD评分≤15:衍生队列6周生存率100%,验证队列86%。
- 动脉乳酸≥12 mmol/L和/或MELD评分≥30:衍生队列6周生存率5%,验证队列10%。
临床怎么用
- 对于难治性静脉曲张出血拟行挽救性TIPS的患者,应检测动脉乳酸和MELD评分以进行风险分层。
- 动脉乳酸≤2.5 mmol/L且MELD≤15者6周生存率>85%,可考虑积极行挽救性TIPS。
- 乳酸≥12 mmol/L和/或MELD≥30者6周死亡率>90%,需谨慎评估获益风险。
局限性
- 回顾性研究设计。
- 仅纳入五中心2007至2017年数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Data about the prognosis of salvage transjugular intrahepatic portosystemic shunt (TIPS) using covered stents for refractory variceal bleeding caused by portal hypertension are scarce. We aimed to assess survival and to identify predictors of mortality in these patients. APPROACH AND RESULTS: One hundred sixty-four patients with cirrhosis from five centers treated with salvage TIPS between 2007 and 2017 were retrospectively divided into a derivation cohort (83 patients) and a validation cohort (81 patients). Comparisons were performed using the Mann-Whitney and Fischer's exact test. Six-week overall survival (OS) was correlated with variables on the day of the TIPS using Kaplan-Meier curves with log-rank test and univariate/multivariate analyses using the Cox model. Eighty-three patients were included in the derivation cohort (male, 78%; age, 55 years, alcohol-associated cirrhosis, 88%; Model for End-Stage Liver Disease [MELD], 19 [15-27]; arterial lactate, 3.7 mmol/L [2.0-8.3]). Six-week OS rate was 58%. At multivariate analysis, the MELD score (OR, 1.064; 95% CI, 1.005-1.126; P = 0.028) and arterial lactate (OR, 1.063; 95% CI, 1.013-1.114; P = 0.032) were associated with 6-week OS. Six-week OS rates were 100% in patients with arterial lactate ≤2.5 mmol/L and MELD score ≤ 15 and 5% in patients with lactate ≥12 mmol/L and/or MELD score ≥ 30. The 81 patients of the validation cohort had similar MELD and arterial lactate level but lower creatinine level (94 vs 106 µmol/L, P = 0.008); 6-week OS was 67%. Six-week OS rates were 86% in patients with arterial lactate ≤2.5 mmol/L and MELD score ≤ 15 and 10% for patients with lactate ≥12 mmol/L and/or MELD score ≥ 30. In the overall cohort, rebleeding rate was 15.8% at 6 weeks, and the acute-on-chronic liver failure grade (OR, 1.699; 95% CI, 1.056-1.663; P = 0.040) was independently associated with rebleeding. CONCLUSIONS: After salvage TIPS, 6-week mortality remains high and can be predicted by MELD score and lactate. Survival rate at 6 weeks was >85% in patients with arterial lactate ≤2.5 mmol/L and MELD score ≤ 15, while mortality was >90% for lactate ≥12 mmol/L and/or MELD score ≥ 30.
引用
- Walter A, Rudler M, Olivas P, et al. Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding. Hepatology. 2021. PMID: 34018627. doi:10.1002/hep.31913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。